Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Piracetam wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Probably helps
4 of 6 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Piracetam and Pramiracetam have evidence — compare verdict strength side-by-side.
1200-4800mg daily in divided doses
Divided into 2-3 doses, Morning and early afternoon, With a choline source
Piracetam powder or capsules
Commonly 400-1200mg/day in divided doses (no robustly validated regimen)
morning
Pramiracetam
2-4 weeks
1-2 weeks
Ongoing
First few days
Weeks
Throughout use
N/A
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Piracetam for reducing the incidence of painful sickle cell disease crises
The Cochrane database of systematic reviews (2016) · Meta analysis · n=169
Although there was no significant difference between the piracetam and placebo periods for the number of days of hospitalisation (P = 0.87) in one trial, inconsistencies in the criteria necessary for hospitalisation during sickle crises did not permit accurate conclusions to be drawn.
Treatment Efficacy of Pharmacotherapies for Frontotemporal Dementia: A Network Meta-Analysis of Randomized Controlled Trials
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry (2023) · Meta analysis · n=243
Compared with placebo, high-dose oxytocin (72 international units) was associated with the greatest improvement in patients' neuropsychiatric symptoms (SMD = -1.17, 95% CIs = -2.25 to -0.08, z = -2.10, p = 0.035).
Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia.
Brain Inj (1991) · Rct
Double-blind placebo-controlled study of pramiracetam 400 mg three times daily in males with brain-injury-related cognitive deficits
Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam.
Neurology (1991) · Rct · n=10
Two-phase, placebo-controlled, enrichment-type trial in 10 probable-Alzheimer's patients
Piracetam and other structurally related nootropics.
Brain Res Brain Res Rev (1994) · Review
Comprehensive review of piracetam-class nootropics (1965-1992), including pramiracetam
Based on meta-analysis of 1002 stroke patients, but showed non-significant increase in death at one month. Evidence is limited and mixed. Conservative effectiveness estimates due to safety concerns.
AI-estimated from published studies. Interpret as directional guidance.
Piracetam has a higher evidence score (9/10 vs 2.5/10) and wins in 3 of 3 categories.
For sharpen focus, Piracetam has a higher relevance score (75 vs 16).
No known interactions between Piracetam and Pramiracetam have been documented in our database. However, always consult a healthcare provider before combining supplements.